KRAS G12C Mutation: Rare Target in Genitourinary Cancers
A new study published in Oncotarget examines the incidence of KRAS G12C mutations in genitourinary cancers, finding them to be rare across the studied cohort. The research highlights that while these mutations are common in other cancers, they appear in only 0.2% of genitourinary tumor specimens.
Why it matters
Understanding the prevalence of specific genetic mutations is critical for the development and application of precision medicine and targeted cancer therapies.
"KRAS G12C mutations occur infrequently in major genitourinary malignancies."
BUFFALO, NY - August 28, 2026 - A new research paper was published in Volume 17 of Oncotarget on August 19, 2026, titled " Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine ."
The study was led by first author Kelly Crane from the Department of Urology at SUNY Upstate Medical University . The corresponding author is K. R. Seetharam Bhat, who is affiliated with the Department of Urology at SUNY Upstate Medical University and Upstate Urology at MVHS .
KRAS is one of the most extensively studied oncogenes in cancer, and the G12C variant has become clinically important following the development of mutation-specific inhibitors. Although KRAS G12C-targeted therapy is established in other malignancies, its frequency and genomic characteristics in genitourinary cancers have remained less well defined.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in